Mari A, Di Felice G, Afferni C, Barletta B, Tinghino R, Sallusto F, Pini C
Department of Immunology, Istituto Superiore di Sanità, Rome, Italy.
J Allergy Clin Immunol. 1996 Jul;98(1):21-31. doi: 10.1016/s0091-6749(96)70222-1.
There is increasing evidence for the relevance of Cupressaceae pollinosis among persons living in geographic areas where these species are native or imported.
Previously reported problems in obtaining valid allergenic extracts to be used in the diagnosis of this winter pollinosis prompted us to assess the value of available Cupressaceae pollen extracts for in vivo and in vitro diagnosis.
Commercial and in-house allergenic extracts from Cupressaceae and Taxodiaceae families were used for skin prick testing and specific IgE detection in six groups of subjects exposed to a high concentration of Cupressaceae pollen.
Four commercial and two in-house Cupressus sempervirens pollen extracts showed low cutaneous reactivity. Positive test results were recorded in 26% of the 713 subjects tested. C. arizonica in-house pollen extracts gave rise to larger cutaneous reactions. Furthermore, the skin prick test response was positive in a greater number of subjects (38%) of the same group. Six commercial immunoassays were able to detect specific IgE to C. sempervirens in rates ranging from 8.1% to 81.1%. Specific IgE to C. arizonica was detected by means of an in-house immunoenzymatic method in 70.3% of 54 patients with suspected "cypress" allergy, and specific IgE to C. sempervirens was detected in 75.9% of these patients by using a commercial system. High rates of cross-reactivity within the Cupressaceae family and with species of the Taxodiaceae family were recorded with both in vivo and in vitro tests.
The use fo C. sempervirens in vivo diagnostics should be carefully evaluated until better characterized extracts are developed. In-house-characterized extracts of C. arizonica seem to be more reliable in the diagnosis of Cupressaceae allergy by means of skin prick testing. the sensitivity of commercially available in vitro methods to detect specific IgE to C. sempervirens should be carefully evaluated; nevertheless, valid results can be obtained with some already available immunoassays.
在这些柏科植物为原生种或引进种的地理区域居住的人群中，柏科花粉症相关性的证据越来越多。
先前报道了在获取用于诊断这种冬季花粉症的有效变应原提取物方面存在的问题，这促使我们评估现有柏科花粉提取物用于体内和体外诊断的价值。
使用来自柏科和杉科的市售及自制变应原提取物，对六组暴露于高浓度柏科花粉的受试者进行皮肤点刺试验和特异性IgE检测。
四种市售和两种自制的地中海柏木花粉提取物显示出较低的皮肤反应性。在713名受试对象中，26%的检测结果呈阳性。自制的亚利桑那柏花粉提取物引起更大的皮肤反应。此外，同一组中更多受试者（38%）的皮肤点刺试验结果呈阳性。六种市售免疫测定法检测地中海柏特异性IgE的比率在8.1%至81.1%之间。通过自制免疫酶法在54例疑似“柏树”过敏患者中检测到70.3%的患者有亚利桑那柏特异性IgE，使用商业系统在这些患者中检测到75.9%的患者有地中海柏特异性IgE。体内和体外试验均记录到柏科家族内部以及与杉科物种之间的高交叉反应率。
在开发出特征更明确的提取物之前，应仔细评估地中海柏在体内诊断中的应用。自制的特征明确的亚利桑那柏提取物通过皮肤点刺试验诊断柏科过敏似乎更可靠。应仔细评估市售体外方法检测地中海柏特异性IgE的敏感性；然而，使用一些现有免疫测定法可获得有效的结果。
